IP Library Granted Patent US 11,382,952
Granted Patent B2
US 11,382,952 · App. 16/110,001 · Granted Jul 12, 2022

Molecular marker for cancer stem cell

Inventors: Toshihiko Torigoe (Sapporo, JP); Yoshihiko Hirohashi (Sapporo, JP); Noriyuki Satoh (Sapporo, JP); Kenjiro Kamiguchi (Sapporo, JP); Rena Morita (Sapporo, JP); Satoshi Nishizawa (Sapporo, JP); Akari Takahashi (Sapporo, JP)
Assignees: Sapporo Medical University; Sumitomo Pharma Co., Ltd.
A61K38/177C07K7/06C12N5/0638C12N15/113C12N15/1138C12Q1/6886G01N33/5017G01N33/574G01N33/57492C12N2310/14C12Q2600/112C12Q2600/118C12Q2600/136C12Q2600/158G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,382,952
App. No.
16/110,001
Granted
Jul 12, 2022
Kind
B2
Abstract

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Claims (8)

1. A method for treating a subject having a tumor comprising administering to the subject an effective amount of a peptide being any of (i) to (iii) below:

(i) Or7c1_34: MYLVTFTGNL (SEQ ID NO: 73)

(ii) a peptide in which the second amino acid from the N terminal of the peptide of (i) is replaced by tryptophan, phenylalanine or methionine, and/or the amino acid at the C terminal of the peptide of (i) is replaced by isoleucine, tryptophan, phenylalanine or methionine; or

(iii) a peptide in which one amino acid is added to the N or C terminus of the peptide of (i) or the peptide of (ii);

wherein said peptide has HLA-A24 binding ability.

2. The method according to claim 1 , wherein the peptide of (i) or (ii) is administered to the subject.

3. The method according to claim 2 , wherein the peptide of (i) is administered to the subject.

4. The method according to claim 1 , wherein the peptide Or7c1_34: MYLVTFTGNL (SEQ ID NO: 73).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2024
From: SUMITOMO PHARMA CO., LTD.
To: SAPPORO MEDICAL UNIVERSITY
Reel/Frame 069340/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2024
From: SAPPORO MEDICAL UNIVERSITY
To: ASSOCIATION FOR KOKICHI KIKUCHI MEMORIAL ACADEMIC PROMOTION
Reel/Frame 069340/0933 →
CHANGE OF NAME Recorded Apr 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059659/0268 →
CHANGE OF NAME Recorded Sep 24, 2019
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 050480/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2019
From: TORIGOE, TOSHIHIKO; HIROHASHI, YOSHIHIKO; SATOH, NORIYUKI; KAMIGUCHI, KENJIRO; MORITA, RENA; NISHIZAWA, SATOSHI; TAKAHASHI, AKARI
To: DAINIPPON SUMITOMO PHARMA CO., LTD.; SAPPORO MEDICAL UNIVERSITY
Reel/Frame 048695/0540 →
Priority Claims (2)
JP 2008-275539 · Oct 27, 2008 · national
JP 2009-068656 · Mar 19, 2009 · national
Continuity (4)
Division 15162833 · May 24, 2016
Division 13967410 · Aug 15, 2013
Division 13126039
Related Publication 20190054141A1 · Feb 21, 2019